Praecis Pharmaceuticals

PRAECIS PHARMACEUTICALS INCORPORATED is a biopharmaceutical company focused on the discovery and development of novel compounds to address unmet medical needs or improve existing therapies. PRAECIS has a novel MetAP-2 inhibitor, PPI-2458, in clinical development for cancer indications, including non-Hodgkin's lymphoma and solid tumors, as well as an innovative drug discovery technology, Direct Select™ ,which enables the generation and practical use of ultra-large libraries for the discovery of orally active compounds for drug development. The Company's corporate headquarters and state-of-the-art research facility are located in Waltham, Massachusetts.